Details der Publikation - Preparation and Characterization of Trimethyl Chitosan /Hyaluronic Acid Composite Encapsulated with LL37 to Promote Wound Healing in an Animal Model

Preparation and Characterization of Trimethyl Chitosan /Hyaluronic Acid Composite Encapsulated with LL37 to Promote Wound Healing in an Animal Model

Abstract Wound treatment is one of the most prevalent concerns and economic burden in healthcare system. Because of antibacterial and re-epithelialization properties, trimethyl chitosan (TMC) has the potential to be used in wound healing dressing. Hyaluronic acid (HA), the main component of the extracellular matrix is capable to activate specific cell signals involved in fibroblast proliferation and new vessel formation, improving the quality of the scars. LL37 peptide promotes wound healing, angiogenesis and also has potential antimicrobial properties. Hence, we aimed to fabricate LL37 encapsulated in TMC-HA composite as a novel topical wound dressing and evaluated its efficacy to accelerate wound closure in an animal model. Composites were optimized based on physical properties such as, porosity, swelling, biodegradation, and mechanical properties. The release of LL37 from the optimized composite (3:3 v/v) was completed during 8 h using bicinchoninic acid assay (BCA) protein quantification kit. LL37-loaded TMC-HA composites displayed antimicrobial activity against Staphylococcus aureus and Pseudomonas aeruginosa. Animal experiments demonstrated the complete wound healing in the group that received LL37-loaded TMC-HA following 16 days of treatment. Based on histological studies, the formation of advanced granulation tissue with significantly higher collagen deposition and re-epithelialized tissues were observed in LL37-loaded TMC-HA-treated wounds. In conclusion, we successfully developed a biodegradable wound healing dressing that promoted healing processes in mice wound model contributed to simultaneous positive effects of the polymers and LL37..

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:29
Enthalten in:	International journal of peptide research and therapeutics - 29(2023), 3 vom: 24. Apr.

Sprache:	Englisch

Beteiligte Personen:	Rezazadeh, Mahboubeh [VerfasserIn] Jalali, Iman [VerfasserIn] Akbari, Vajihe [VerfasserIn] Minaiyan, Mohsen [VerfasserIn] Najafabadi, Alireza Hassani [VerfasserIn] Taheri, Azade [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	35.76$jAminosäuren$jPeptide$jEiweiße$XBiochemie
Themen:	Animal study LL37 peptide Topical formulation Wound healing

Anmerkungen:	© The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:	10.1007/s10989-023-10513-6

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2134641371

Internformat


LEADER	01000naa a22002652 4500
001	OLC2134641371
003	DE-627
005	20230510162857.0
007	cr uuu---uuuuu
008	230510s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s10989-023-10513-6 \|2 doi
035			\|a (DE-627)OLC2134641371
035			\|a (DE-He213)s10989-023-10513-6-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 540 \|q VZ
084			\|a 35.76$jAminosäuren$jPeptide$jEiweiße$XBiochemie \|2 bkl
100	1		\|a Rezazadeh, Mahboubeh \|e verfasserin \|0 (orcid)0000-0003-4121-9642 \|4 aut
245	1	0	\|a Preparation and Characterization of Trimethyl Chitosan /Hyaluronic Acid Composite Encapsulated with LL37 to Promote Wound Healing in an Animal Model
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
520			\|a Abstract Wound treatment is one of the most prevalent concerns and economic burden in healthcare system. Because of antibacterial and re-epithelialization properties, trimethyl chitosan (TMC) has the potential to be used in wound healing dressing. Hyaluronic acid (HA), the main component of the extracellular matrix is capable to activate specific cell signals involved in fibroblast proliferation and new vessel formation, improving the quality of the scars. LL37 peptide promotes wound healing, angiogenesis and also has potential antimicrobial properties. Hence, we aimed to fabricate LL37 encapsulated in TMC-HA composite as a novel topical wound dressing and evaluated its efficacy to accelerate wound closure in an animal model. Composites were optimized based on physical properties such as, porosity, swelling, biodegradation, and mechanical properties. The release of LL37 from the optimized composite (3:3 v/v) was completed during 8 h using bicinchoninic acid assay (BCA) protein quantification kit. LL37-loaded TMC-HA composites displayed antimicrobial activity against Staphylococcus aureus and Pseudomonas aeruginosa. Animal experiments demonstrated the complete wound healing in the group that received LL37-loaded TMC-HA following 16 days of treatment. Based on histological studies, the formation of advanced granulation tissue with significantly higher collagen deposition and re-epithelialized tissues were observed in LL37-loaded TMC-HA-treated wounds. In conclusion, we successfully developed a biodegradable wound healing dressing that promoted healing processes in mice wound model contributed to simultaneous positive effects of the polymers and LL37.
650		4	\|a Wound healing
650		4	\|a Topical formulation
650		4	\|a LL37 peptide
650		4	\|a Animal study
700	1		\|a Jalali, Iman \|4 aut
700	1		\|a Akbari, Vajihe \|4 aut
700	1		\|a Minaiyan, Mohsen \|4 aut
700	1		\|a Najafabadi, Alireza Hassani \|4 aut
700	1		\|a Taheri, Azade \|4 aut
773	0	8	\|i Enthalten in \|t International journal of peptide research and therapeutics \|d Springer Netherlands, 2005 \|g 29(2023), 3 vom: 24. Apr. \|h Online-Ressource \|w (DE-627)490716237 \|w (DE-600)2192632-3 \|w (DE-576)254902375 \|x 1573-3904 \|7 nnns
773	1	8	\|g volume:29 \|g year:2023 \|g number:3 \|g day:24 \|g month:04
856	4	0	\|u https://dx.doi.org/10.1007/s10989-023-10513-6 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2131
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 35.76$jAminosäuren$jPeptide$jEiweiße$XBiochemie \|q VZ \|0 181571129 \|0 (DE-625)181571129
951			\|a AR
952			\|d 29 \|j 2023 \|e 3 \|b 24 \|c 04

Preparation and Characterization of Trimethyl Chitosan /Hyaluronic Acid Composite Encapsulated with LL37 to Promote Wound Healing in an Animal Model

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände